shutterstock-195533942-web
360b / Shutterstock.com
3 February 2015Americas

Bayer seeks to block Nexavar generic at Delaware court

Bayer and Onyx Pharmaceuticals have sued generic drug maker Mylan in an attempt to stop it from developing a version of liver cancer drug Nexavar (sorafenib tosylate).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
30 October 2017   Bayer Healthcare and Mylan have settled their differences over a generic version of Bayer’s liver cancer drug Nexavar (sorafenib tosylate).

More on this story

Americas
30 October 2017   Bayer Healthcare and Mylan have settled their differences over a generic version of Bayer’s liver cancer drug Nexavar (sorafenib tosylate).

More on this story

Americas
30 October 2017   Bayer Healthcare and Mylan have settled their differences over a generic version of Bayer’s liver cancer drug Nexavar (sorafenib tosylate).